title: Targeting polo-like kinase 1 in acute myeloid leukemia.
abstract: Polo-like kinase 1 (Plk1) plays a number of important roles in the passage of cells through mitosis. It is expressed at high levels in a variety of malignancies, including acute myeloid leukemia (AML). Inhibition of Plk1 results in cell cycle arrest and apoptosis, and has anti-tumor effects in pre-clinical models. A number of Plk1 inhibitors have been developed, some of which have entered clinical trials. Of these, volasertib (BI6727) has been most extensively studied clinically in AML. Volasertib has demonstrated antileukemic activity in AML, both as a single agent and when combined with low-dose cytarabine. It is well tolerated, with the major toxicity being reversible myelosuppression. A recently completed phase III clinical trial in older AML patients will address the question of whether adding this agent to low-dose cytarabine is associated with a survival advantage.
authors.affiliation: Division of Hematology, Department of Medicine, University of Alberta, 4-112 Clinical Sciences Building, 11350-83 Avenue, Edmonton, AB, Canada T6G 2G3.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Brandwein
keywords: acute myeloid leukemia; chemotherapy; leukemia; polo-like kinases; volasertib
references.citation: Curr Biol. 2007 Feb 20;17(4):304-15
references.pmid: 17291761
references.citation: Oncogene. 2002 Sep 9;21(40):6195-200
references.pmid: 12214249
references.citation: Clin Cancer Res. 2011 May 15;17(10):3420-30
references.pmid: 21459796
references.citation: Cancer Cell. 2005 Mar;7(3):275-86
references.pmid: 15766665
references.citation: Oncogene. 2005 Jan 10;24(2):260-6
references.pmid: 15640841
references.citation: J Clin Oncol. 2012 Dec 20;30(36):4515-23
references.pmid: 22987078
references.citation: JAMA. 2000 Jan 26;283(4):479-80
references.pmid: 10659871
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2670-7
references.pmid: 22689805
references.citation: Expert Opin Drug Discov. 2014 Jul;9(7):773-89
references.pmid: 24819909
references.citation: Br J Haematol. 2013 Aug;162(4):517-24
references.pmid: 23789936
references.citation: Blood. 2009 Jul 16;114(3):659-62
references.pmid: 19458358
references.citation: Leukemia. 2009 Sep;23(9):1564-76
references.pmid: 19421227
references.citation: PLoS One. 2013;8(3):e58424
references.pmid: 23520509
references.citation: Leuk Lymphoma. 2007 Nov;48(11):2179-83
references.pmid: 17943598
references.citation: J Biol Chem. 2004 Aug 27;279(35):36841-54
references.pmid: 15210710
references.citation: Curr Biol. 2007 Feb 20;17(4):316-22
references.pmid: 17291758
references.citation: Expert Opin Investig Drugs. 2010 Jan;19(1):27-43
references.pmid: 20001553
references.citation: Proc Natl Acad Sci U S A. 2003 May 13;100(10):5789-94
references.pmid: 12732729
references.citation: Am J Hematol. 2015 Jan;90(1):27-30
references.pmid: 25251041
references.citation: Mol Cancer Ther. 2012 Apr;11(4):1006-16
references.pmid: 22319201
references.citation: Blood. 2014 Aug 28;124(9):1426-33
references.pmid: 25006120
references.citation: Clin Cancer Res. 2009 May 1;15(9):3094-102
references.pmid: 19383823
references.citation: Blood. 2010 Jul 22;116(3):354-65
references.pmid: 20385793
references.citation: Clin Cancer Res. 2014 Mar 15;20(6):1656-65
references.pmid: 24493827
references.citation: Nat Rev Drug Discov. 2010 Aug;9(8):643-60
references.pmid: 20671765
references.citation: Cancer. 2006 Mar 1;106(5):1090-8
references.pmid: 16435386
references.citation: Int J Cancer. 2000 Nov 20;89(6):535-6
references.pmid: 11102900
references.citation: Cancer. 2007 Mar 15;109(6):1114-24
references.pmid: 17315155
references.citation: Blood. 2009 Aug 6;114(6):1166-73
references.pmid: 19470696
references.citation: Oncogene. 2009 Jan 8;28(1):107-16
references.pmid: 18820703
references.citation: Oncogene. 1997 Feb 6;14(5):543-9
references.pmid: 9053852
references.citation: Pathol Res Pract. 2000;196(11):753-9
references.pmid: 11186170
references.citation: Mol Biol Cell. 2004 Dec;15(12 ):5623-34
references.pmid: 15469984
references.citation: Clin Cancer Res. 2010 Sep 15;16(18):4666-74
references.pmid: 20682708
references.citation: Hematol Oncol. 2015 Jun;33(2):57-66
references.pmid: 24777753
references.citation: Br J Haematol. 2013 Oct;163(2):214-22
references.pmid: 24033250
references.citation: Leukemia. 2013 Apr;27(4):879-88
references.pmid: 23164802
references.citation: Blood. 2005 Dec 1;106(12):3733-9
references.pmid: 16076867
references.citation: J Clin Oncol. 2010 Feb 1;28(4):562-9
references.pmid: 20026804
references.citation: Indian J Cancer. 2014 Jan-Mar;51(1):40-4
references.pmid: 24947095
references.citation: Mol Cancer Ther. 2012 Mar;11(3):700-9
references.pmid: 22188812
references.citation: Blood. 2014 Jul 10;124(2):273-6
references.pmid: 24855211
references.citation: Br J Cancer. 2004 Feb 23;90(4):815-21
references.pmid: 14970859
references.citation: Blood. 2006 Jul 1;108(1):63-73
references.pmid: 16522815
references.citation: Blood. 2005 Aug 15;106(4):1154-63
references.pmid: 15870183
references.citation: Eur J Cancer. 2012 Jan;48(2):179-86
references.pmid: 22119200
references.citation: Cancer. 2005 May 15;103(10):2082-90
references.pmid: 15830348
references.citation: Blood. 2001 Sep 1;98 (5):1312-20
references.pmid: 11520776